Hosted by the American College of Toxicology in Collaboration with the British Toxicology Society and the Society of Toxicologic Pathology.
Speakers: Simone Nicholson, PhD, DABT, Senior Toxicologist, Biologics Safety Assessment, MedImmune LLC; Hervé Lebrec, PharmD, PhD, DABT, Scientific Director, Nonclinical Safety Sciences, Amgen Inc.; Shawn Heidel, DVM, PhD, Vice President and Head, Global Safety Assessment, Covance Laboratories, Inc.; and Ken Hastings, DrPH, DABT, ATS, Hastings Toxicology Consulting, LLC
Abstract for Safety Assessment of Monoclonal Antibodies for Immunosuppressants and Anti-Inflammatory Agents:
Immune-Mediated Inflammatory Disease (IMID) encompasses a broad category of over 100 related diseases in which the person's immune system attacks his or her own tissue. Pathogenesis is amplified by inflammatory cytokines and is self-perpetuating due to persistence of self-antigens and redundancy in inflammatory pathways. Over the years, the therapeutic goal in IMID has shifted from control of symptoms toward achieving clinical remission and tissue healing in order to prevent disease progression. Monoclonal antibodies (mAbs) have been used either individually or in combinations to combat the mechanisms that drive IMID pathogenesis.
View Webinar Recording
Webinar materials are property of the speaker and the American College of Toxicology and are intended for use by the host society and co-host societies' members for educational purposes only. Any distribution or copy of the materials is prohibited. By downloading from the link provided you agree to the terms expressed above.